RxDoctor Payments Data

Sintya Barreiro

Psychiatric/Mental Health · Oldsmar, FLNPI 1760135487

Payments from drug & device makers

$518in general payments, 2019–2025

Across 18 payments — averaging $28.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$138
  • Insmed, Inc.$116
  • Takeda Pharmaceuticals U.S.A., Inc.$96
  • Teva Pharmaceuticals USA, Inc.$41
  • Johnson & Johnson$39
  • Vanda Pharmaceuticals Inc.$24
  • plus $64 from 3 others

What the payments were for

  • Food & beverage$518100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$518 in reported general payments places this provider in the 45th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$50,841
Medicare patients
110
Services billed
739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate16$142,170
VraylarCariprazine Hcl46$68,412
CaplytaLumateperone Tosylate13$20,471
Aripiprazole153$16,999
RexultiBrexpiprazole11$16,351
TrintellixVortioxetine Hydrobromide18$8,983
Paliperidone ErPaliperidone34$8,645
Quetiapine Fumarate326$5,578
Duloxetine Hcl183$3,467
Buspirone Hcl255$3,380
Lamotrigine218$2,660
Lurasidone Hcl25$2,068
Hydroxyzine Hcl138$1,856
Trazodone Hcl190$1,780
Olanzapine62$1,384

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$22$142,17016 claims
AbbVieVraylar$138$68,41246 claims
Otsuka America Pharmaceutical, Inc.Rexulti$20$16,35111 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$96$8,98318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Oldsmar

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →